CLINICAL ROLE -
August 7th 2025
Designed for use in Celiac disease, larazotide was found to hasten resolution of multisystem inflammatory syndrome symptoms in children with the condition.
August 6th 2025
Promoting heart health in children reduces obesity and chronic disease risks, ensuring better overall well-being into adulthood.
Amid dropping vaccination rates, pharmacists are key to educating parents and assuaging concerns.
The FDA expands tocilizumab-anoh's approval for treating cytokine release syndrome (CRS), enhancing treatment options for patients aged 2 and older.
The FDA approved fremanezumab for pediatric migraine prevention, offering a new treatment option for children and adolescents aged 6 to 17.